<DOC>
	<DOCNO>NCT02875340</DOCNO>
	<brief_summary>The objective study assess safety , tolerability , pharmacokinetics efficacy VAL401 treatment patient locally advanced metastatic non-small cell lung adenocarcinoma .</brief_summary>
	<brief_title>A Study VAL401 Treatment Patients With Locally Advanced Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This Phase II , open label study ass efficacy , safety tolerability VAL401 treatment patient locally advanced metastatic non-small cell lung adenocarcinoma failure least one prior chemotherapeutic regimen . Eligible patient enrol single cohort treat VAL401 , give oral capsule . VAL401 formulation Risperidone ( active pharmaceutical ingredient ) liquid lipid fill capsule .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Pathologically confirm diagnosis Stage IIIB Stage IV adenocarcinoma lung . Patients mixed histology eligible adenocarcinoma predominant histology . Measurable disease accord RECIST version 1.1 . Prior chemotherapy relapse metastatic non small cell lung cancer . Life expectancy least 3 month . Negative human chorionic gonadotropin ( hCG ) test woman childbearing potential ( defined woman ≤ 50 year age history amenorrhea ≤ 12 month prior study screen ) . Sexually active male female patient childbearing potential must agree use effective method birth control e.g . barrier method spermicide , oral parenteral contraceptive and/or intrauterine device , entire duration study 1 month final administration VAL401 . Note female patient may surgically sterile ( appropriate documentation patient 's medical record ) . Ability give write , informed consent prior studyspecific screening procedure understanding consent may withdraw patient time without prejudice . Patient capable understanding protocol requirement , willing able comply study protocol procedure , sign informed consent document . Radiotherapy surgery ( biopsy ) within 4 week prior Cycle 1 Day 1 . Any chemotherapy regimen ( include investigational agent ) delay toxicity 6 week Cycle 1 Day 1 , receive chemotherapy regimen give continuously weekly basis limit potential delayed toxicity within 2 week prior Cycle 1 Day 1 . Palliative treatment regimen , concomitant drug regimen permit stable toxicity , record concomitant medication ( include herbal ) . Pregnant lactate female patient . Active hepatitis B C active liver disease ( malignancy ) . Any active , clinically significant , viral , bacterial , systemic fungal infection within 2 week prior Cycle 1 Day 1 ; cytomegalovirus may present provide require concomitant antiviral treatment record appropriately . Known human immunodeficiency virus positivity . History clinically significant cardiac condition , include ischemic cardiac event , myocardial infarction unstable cardiac disease 3 month prior Cycle 1 Day 1 . Active brain metastasis ( define stable &lt; 4 week and/or symptomatic and/or require treatment anticonvulsant steroid and/or leptomeningeal disease ) . Any known contraindication Risperidone patient would eligible receive treatment define Special Warnings Precautions section local label Risperidone . Any medical history Investigator 's opinion would jeopardise compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>